While further prospective studies are required to validate the connection between increased serum galectin-3 and the onset and acute exacerbation of COPD, this meta-analysis supports the potential utility of serum galectin-3 as a biomarker for identifying patients with COPD and AECOPD. Here, LGALS3 is linked to chronic obstructive pulmonary disease.